fda ruling on compounded tirzepatide Eli Lilly just issued a public warning to the compounding industry. In a recent open letter, the pharmaceutical company raised concerns about products being combined with vitamin B12 and marketed in The FDA says it's standing

10.1007/s00253-020-10657-1 Appl Microbiol Biotechnol

Serious but rare adverse effects require awareness: Pancreatitis : Acute pancreatitis has been reported with GLP-1 receptor agonists

Chronic Overeating & Appetite Dysregulation For patients whose weight is driven by an inability to feel satisfied eating past fullness, chronic hunger between meals, or strong food cravings semaglutide directly addresses the neurological hunger-satiety signaling that causes this pattern

B12 injections help keep these levels low and help prevent heart disease

Protein Intake and Muscle Preservation One of the challenges of rapid weight loss associated with semaglutide is the potential loss of lean muscle mass